Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jochen K. Lennerz"'
Autor:
Colin D. Weekes, James C. Cusack, Christine E. Eyler, Lipika Goyal, Jochen K. Lennerz, Emily E. Van Seventer, Jill N. Allen, Jennifer Y. Wo, Peter J. Ulintz, Andrew X. Zhu, Hui Zheng, Susan G.R. McDuff, Theodore S. Hong, Daniel Kim, David P. Ryan, Mehlika Hazar-Rethinam, Jeffrey W. Clark, Ryan B. Corcoran, Isobel J Fetter, Brandon Nadres, Lawrence S. Blaszkowsky, Aparna Raj Parikh, Karin M. Hardiman
Publikováno v:
JCO Precis Oncol
PURPOSE This study was designed to assess the ability of perioperative circulating tumor DNA (ctDNA) to predict surgical outcome and recurrence following neoadjuvant chemoradiation for locally advanced rectal cancer (LARC). MATERIALS AND METHODS Twen
Autor:
Ibiayi Dagogo-Jack, Russell W. Madison, Jochen K. Lennerz, Kuei-Ting Chen, Julia F. Hopkins, Alexa B. Schrock, Lauren L. Ritterhouse, Ashley Lester, Keith A. Wharton Jr, Mari Mino-Kenudson, Natalie Danziger, Yin P. Hung, Douglas A. Mata, Jeffrey S. Ross
Publikováno v:
JCO Precision Oncology.
PURPOSE Mesothelioma is an aggressive malignancy with heterogeneous outcomes that are partly driven by the differential efficacy of existing therapies across histologic types and sites of origin. Large-scale molecular analysis of mesothelioma and its
Autor:
Eric B. Haura, A. John Iafrate, Alexander Drilon, Alexander I. Spira, Shivaani Kummar, Sai-Hong Ignatius Ou, Martin S. Taylor, Long P. Le, Viola W. Zhu, Jochen K. Lennerz, Mari Mino-Kenudson, Ryma Benayed, Maria E. Arcila, Theresa A. Boyle, Robert C. Doebele, Anna F. Farago, Alice T. Shaw, Nora Horick, Dara L. Aisner
Publikováno v:
JCO Precision Oncology. :1-12
Purpose Gene rearrangements that involve NTRK1/2/3 can generate fusion oncoproteins that contain the kinase domains of TRKA/B/C, respectively. These fusions are rare in non–small-cell lung cancer (NSCLC), with frequency previously estimated to be <
Autor:
Valentina Nardi, Miguel Rivera, Hayley Robinson, Florian J. Fintelmann, Jennifer S. Temel, Zofia Piotrowska, Mari Mino-Kenudson, Subba R. Digumarthy, Inga T. Lennes, A. John Iafrate, Jessica J. Lin, Jochen K. Lennerz, Dora Dias-Santagata, Meghan J. Mooradian, Christopher G Azzolli, Julie M. Batten, Lecia V. Sequist, Justin F. Gainor, Ginger Y. Jiang, Jo-Anne O. Shepard, Alice T. Shaw, Long P. Le, Martha B. Pitman, Ibiayi Dagogo-Jack, Anna F. Farago, Vania Nosé, Rebecca S. Heist
Publikováno v:
JCO Precision Oncology. :1-13
Purpose Targeted therapy is the cornerstone of treatment of advanced EGFR-mutant non–small-cell lung cancer (NSCLC). Next-generation sequencing (NGS), the preferred method for genotyping, typically requires several weeks. Here, we assessed workflow
Autor:
Ibiayi, Dagogo-Jack, Christopher G, Azzolli, Florian, Fintelmann, Mari, Mino-Kenudson, Anna F, Farago, Justin F, Gainor, Ginger, Jiang, Zofia, Piotrowska, Rebecca S, Heist, Inga T, Lennes, Jennifer S, Temel, Meghan J, Mooradian, Jessica J, Lin, Subba R, Digumarthy, Julie M, Batten, Hayley, Robinson, Vania, Nose, Miguel, Rivera, Valentina, Nardi, Dora, Dias-Santagata, Long P, Le, Lecia V, Sequist, Martha, Pitman, Jo-Anne O, Shepard, Alice T, Shaw, A John, Iafrate, Jochen K, Lennerz
Publikováno v:
JCO precision oncology. 2018
Targeted therapy is the cornerstone of treatment of advancedWe performed rapid testing forBetween January 2015 and September 2017, we performed 243 rapidRapid genotyping facilitates earlier initiation of EGFR-directed therapies without compromising N
Autor:
Anna F, Farago, Martin S, Taylor, Robert C, Doebele, Viola W, Zhu, Shivaani, Kummar, Alexander I, Spira, Theresa A, Boyle, Eric B, Haura, Maria E, Arcila, Ryma, Benayed, Dara L, Aisner, Nora K, Horick, Jochen K, Lennerz, Long P, Le, A John, Iafrate, Sai-Hong I, Ou, Alice T, Shaw, Mari, Mino-Kenudson, Alexander, Drilon
Publikováno v:
JCO precision oncology. 2018
Gene rearrangements involvingWe compiled a database of NSCLC cases harboringWe identified 11 NSCLC cases harboring